Tag
3 articles
Reid Hoffman is leaving Microsoft’s board to focus on his AI drug discovery startup, Manus. His departure marks a shift from corporate governance to hands-on entrepreneurship.
LinkedIn co-founder Reid Hoffman has launched an AI drug discovery startup and argues that doctors should routinely seek AI second opinions, calling failure to do so 'bordering on malpractice.'
Reid Hoffman suggests AI token usage can indicate adoption rates but warns against treating it as a direct productivity measure, emphasizing the need for contextual analysis.
